AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect ...